Ragon Institute of Mass General, MIT, and Harvard
Joselyn N. Allen, PhD, currently serves as the Research Program Manager for Strategic Research Development and Communications at the Ragon Institute of Mass General, MIT, and Harvard, and is the Founder and Owner of SynSciComm, LLC, which provides communication support for the science community. With extensive experience as a Professional Scientific Illustrator and a Postdoctoral Researcher at the National Institute of Diabetes and Digestive and Kidney Diseases, Joselyn has a strong background in molecular cloning and multi-omics strategies. Teaching experience includes roles as an Instructor and Graduate Teaching Assistant at the Foundation for Advanced Education in Sciences and Penn State University, respectively. Joselyn possesses a Ph.D. in Immunology and Infectious Diseases from Penn State University and a Bachelor of Science from the University of the Virgin Islands.
This person is not in any offices
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.